Latest News

This regulation adopts "no significant risk" levels in Section 12705, subsection (b), for the following chemicals: Arsenic, Butylated hydroxyanisole, Cadmium, and Chromium (hexavalent compounds). 

This regulation adopts "no significant risk" levels for Hexachlorodibenzodioxin (HCDD) of 0.0002 microgram per day and 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) of 0.000005 microgram per day. 

This regulation adopts no significant risk levels for Benzyl chloride of 4 micrograms per day and Bromodichloromethane of 5 micrograms per day. 

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Abamectin. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Malathion, Chlorpyrifos, and Bensulfuron Methyl. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

The purpose of this regulation is to provide a "safe harbor" level for toluene of 7,000 mlcrograms per day. 

OEHHA has provided a number of comments on the exposure assessment methodology and conclusions on the draft EAD for Abamectin. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Permethrin. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Bifenthrin. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD and EAD for Bromoxynil Octanoate. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.